import { BlogArticle } from "./articles";

export const trtAndStatinsArticle: BlogArticle = {
  slug: "trt-and-statins",
  title: "TRT and Statins: Can You Take Testosterone with Cholesterol Medication?",
  description:
    "Yes — statins and TRT are commonly co-prescribed. But the combination requires understanding: statin myopathy risk, testosterone's liver metabolism, HDL implications, and how to monitor both safely.",
  publishedAt: "2026-03-29",
  readingTime: "12 min read",
  category: "protocol",
  keywords: [
    "TRT and statins",
    "testosterone and statins",
    "can you take statins on TRT",
    "testosterone cholesterol medication",
    "TRT cardiovascular risk",
    "statins and testosterone",
  ],
  content: `
<p>Statins are among the most commonly prescribed drugs in the world. If you're a man in your 40s or 50s evaluating TRT, there's a meaningful chance your doctor has already recommended a statin — or will. The question comes up constantly: <strong>can you take testosterone while on a statin?</strong></p>
<p>The short answer is yes. There is no direct contraindication between statins and TRT. They are routinely co-prescribed. But the combination requires some knowledge — because statins and testosterone share metabolic pathways, create overlapping side effects, and affect lipids in ways that need to be tracked.</p>
<p>This article explains the pharmacology, the real risks, what to monitor, and what the research actually shows about statins + testosterone in combination.</p>

<h2>The Short Answer: Yes, They're Compatible</h2>
<p>There is no interaction listed between testosterone and statins in major drug interaction databases. They do not have additive toxicity at standard doses, and there is no documented case series of harm from the combination at therapeutic levels.</p>
<p>In practice, men on TRT who have cardiovascular risk factors are frequently prescribed statins simultaneously. The TRAVERSE trial — the largest RCT of testosterone safety — enrolled men who were at elevated cardiovascular risk, including many who were on statins. The trial found no increase in major adverse cardiovascular events (MACE) in the testosterone group.</p>
<p>What matters is the nuance: how statins and testosterone interact at the metabolic level, and what specific variables to monitor when you're on both.</p>

<h2>How Statins Work (Brief Background)</h2>
<p>Statins inhibit HMG-CoA reductase — the rate-limiting enzyme in the liver's cholesterol synthesis pathway. This reduces LDL-C and, to varying degrees, reduces cardiovascular event risk in high-risk populations.</p>
<p>The HMG-CoA pathway also produces precursors for testosterone and other steroid hormones. Theoretically, statins could reduce testosterone production by limiting substrate availability. In practice, the evidence is mixed — some trials show modest testosterone reductions with statins; others show no effect or even improvement in men with metabolic syndrome.</p>

<h2>Do Statins Lower Testosterone?</h2>
<p>This is a real question, and the evidence is nuanced:</p>
<table style="width:100%; border-collapse:collapse; margin: 16px 0;">
  <thead>
    <tr style="background:#1e1e2e;">
      <th style="padding:10px; text-align:left; border:1px solid #2a2a3a;">Study / Source</th>
      <th style="padding:10px; text-align:left; border:1px solid #2a2a3a;">Finding</th>
      <th style="padding:10px; text-align:left; border:1px solid #2a2a3a;">Context</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td style="padding:10px; border:1px solid #2a2a3a;">Schooling et al. 2013 (meta-analysis, 4,462 men)</td>
      <td style="padding:10px; border:1px solid #2a2a3a;">Statins reduced total T by ~0.66 nmol/L (~19 ng/dL)</td>
      <td style="padding:10px; border:1px solid #2a2a3a;">Modest reduction; not clinically symptomatic for most men</td>
    </tr>
    <tr>
      <td style="padding:10px; border:1px solid #2a2a3a;">Stanworth et al. 2009</td>
      <td style="padding:10px; border:1px solid #2a2a3a;">No significant difference in T between statin users vs. non-users</td>
      <td style="padding:10px; border:1px solid #2a2a3a;">Confounded by metabolic syndrome correlation (statin users have more comorbidities)</td>
    </tr>
    <tr>
      <td style="padding:10px; border:1px solid #2a2a3a;">Pellitero et al. 2011</td>
      <td style="padding:10px; border:1px solid #2a2a3a;">Statins associated with reduced T in obese men with metabolic syndrome</td>
      <td style="padding:10px; border:1px solid #2a2a3a;">Confounded by the obesity itself as the primary driver</td>
    </tr>
    <tr>
      <td style="padding:10px; border:1px solid #2a2a3a;">Chua et al. 2019 (cross-sectional, 4,250 men)</td>
      <td style="padding:10px; border:1px solid #2a2a3a;">Atorvastatin and simvastatin users had lower T; rosuvastatin and pravastatin showed minimal effect</td>
      <td style="padding:10px; border:1px solid #2a2a3a;">Suggests lipophilic statins (atorva/simva) have more effect than hydrophilic (rosuva/prava)</td>
    </tr>
  </tbody>
</table>
<p><strong>Practical implication:</strong> If you're on a lipophilic statin (atorvastatin, simvastatin) and experiencing low-T symptoms, the statin is a worth evaluating as a contributing variable — not necessarily the cause. If your TRT is well-managed, this is largely irrelevant because exogenous testosterone bypasses the precursor supply problem entirely.</p>

<h2>Shared Liver Metabolism: The CYP3A4 Pathway</h2>
<p>This is the most pharmacologically relevant interaction. Both testosterone esters (cypionate, enanthate) and several statins are metabolized by <strong>CYP3A4</strong> in the liver.</p>

<table style="width:100%; border-collapse:collapse; margin: 16px 0;">
  <thead>
    <tr style="background:#1e1e2e;">
      <th style="padding:10px; text-align:left; border:1px solid #2a2a3a;">Statin</th>
      <th style="padding:10px; text-align:left; border:1px solid #2a2a3a;">CYP3A4 Reliance</th>
      <th style="padding:10px; text-align:left; border:1px solid #2a2a3a;">Interaction Significance with TRT</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td style="padding:10px; border:1px solid #2a2a3a;">Atorvastatin (Lipitor)</td>
      <td style="padding:10px; border:1px solid #2a2a3a;">High</td>
      <td style="padding:10px; border:1px solid #2a2a3a;">Mild competition; not clinically significant at standard TRT doses</td>
    </tr>
    <tr>
      <td style="padding:10px; border:1px solid #2a2a3a;">Simvastatin (Zocor)</td>
      <td style="padding:10px; border:1px solid #2a2a3a;">High</td>
      <td style="padding:10px; border:1px solid #2a2a3a;">Same as atorvastatin; minimal clinical impact</td>
    </tr>
    <tr>
      <td style="padding:10px; border:1px solid #2a2a3a;">Rosuvastatin (Crestor)</td>
      <td style="padding:10px; border:1px solid #2a2a3a;">Low (not CYP3A4)</td>
      <td style="padding:10px; border:1px solid #2a2a3a;">Minimal metabolic interaction with testosterone</td>
    </tr>
    <tr>
      <td style="padding:10px; border:1px solid #2a2a3a;">Pravastatin (Pravachol)</td>
      <td style="padding:10px; border:1px solid #2a2a3a;">Low (not CYP3A4)</td>
      <td style="padding:10px; border:1px solid #2a2a3a;">Minimal metabolic interaction with testosterone</td>
    </tr>
    <tr>
      <td style="padding:10px; border:1px solid #2a2a3a;">Fluvastatin (Lescol)</td>
      <td style="padding:10px; border:1px solid #2a2a3a;">CYP2C9 primary</td>
      <td style="padding:10px; border:1px solid #2a2a3a;">Minimal interaction with testosterone</td>
    </tr>
  </tbody>
</table>

<p>At clinical TRT doses (100–200mg testosterone cypionate per week), this CYP3A4 competition is not a meaningful clinical concern. Where it becomes more relevant is with <strong>oral testosterone</strong> (Jatenzo, Kyzatrex) — which has significant hepatic first-pass metabolism and may produce more interaction with CYP3A4-dependent statins than injectable or transdermal routes.</p>

<div style="border: 1px solid #2a2a3a; border-radius: 8px; padding: 16px; margin: 24px 0; background: #12121a;">
  <p style="font-weight: 600; margin-bottom: 8px;">⚠️ Oral TRT + CYP3A4 Statins</p>
  <p>If you're on Jatenzo or Kyzatrex AND atorvastatin or simvastatin, tell your prescriber. The interaction isn't severe, but statin levels can rise modestly when CYP3A4 is occupied. Rosuvastatin or pravastatin are safer companions for oral TRT.</p>
</div>

<h2>The Real Risk to Know: Statin Myopathy on TRT</h2>
<p>This is the most underappreciated interaction between statins and testosterone.</p>
<p>Statin myopathy — muscle pain, weakness, and in rare cases rhabdomyolysis — affects 5–10% of statin users. The risk increases with:</p>
<ul>
  <li>Higher statin doses</li>
  <li>Intense exercise</li>
  <li>Testosterone levels at the high end of range (or supraphysiologic)</li>
  <li>Adding anabolic hormones to an existing statin regimen</li>
</ul>
<p>Here's the issue with TRT specifically: <strong>testosterone increases muscle protein synthesis and training intensity</strong>. Men on TRT often exercise harder and more consistently than before. This increases both the mechanical and metabolic stress on muscle tissue — which is the same tissue statins are taxing via the CoQ10/mitochondria pathway.</p>
<p>A man who tolerated atorvastatin fine for two years may begin experiencing muscle fatigue and soreness within months of starting TRT — not because TRT caused it, but because the combination of more intense exercise plus statin myopathy crossed a symptom threshold that was previously sub-clinical.</p>

<h3>How to Tell If It's Myopathy</h3>
<ul>
  <li>Muscle aches occurring at rest, not just post-exercise</li>
  <li>Symmetric proximal muscle weakness (thighs, upper arms)</li>
  <li>Fatigue disproportionate to training load</li>
  <li>Elevated creatine kinase (CK) on bloodwork — get this checked if symptoms appear</li>
</ul>

<h3>What to Do</h3>
<ol>
  <li>Get CK level at baseline before combining statin + TRT</li>
  <li>If myopathy symptoms appear, check CK immediately</li>
  <li>Discuss with prescriber: switching statin (atorvastatin to rosuvastatin), reducing dose, or taking a statin holiday</li>
  <li>Consider CoQ10 supplementation (100–200mg/day) — evidence is mixed but low-risk and widely used for statin myopathy management</li>
</ol>

<h2>How TRT Affects the Lipid Panel (What Statins Are Trying to Protect)</h2>
<p>Understanding the interaction requires knowing what TRT actually does to your lipids — because statins and TRT can partially counteract each other's effects in one specific area:</p>

<table style="width:100%; border-collapse:collapse; margin: 16px 0;">
  <thead>
    <tr style="background:#1e1e2e;">
      <th style="padding:10px; text-align:left; border:1px solid #2a2a3a;">Lipid Marker</th>
      <th style="padding:10px; text-align:left; border:1px solid #2a2a3a;">TRT Effect</th>
      <th style="padding:10px; text-align:left; border:1px solid #2a2a3a;">Statin Effect</th>
      <th style="padding:10px; text-align:left; border:1px solid #2a2a3a;">Net Result on Both</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td style="padding:10px; border:1px solid #2a2a3a;">LDL-C</td>
      <td style="padding:10px; border:1px solid #2a2a3a;">Neutral to mildly reduced</td>
      <td style="padding:10px; border:1px solid #2a2a3a;">Strongly reduced (30–50%)</td>
      <td style="padding:10px; border:1px solid #2a2a3a;">Net reduction — favorable</td>
    </tr>
    <tr>
      <td style="padding:10px; border:1px solid #2a2a3a;">HDL-C</td>
      <td style="padding:10px; border:1px solid #2a2a3a;">Modestly reduced (5–15% with injectable)</td>
      <td style="padding:10px; border:1px solid #2a2a3a;">Slightly reduced or neutral</td>
      <td style="padding:10px; border:1px solid #2a2a3a;">Modest combined reduction — track carefully if baseline HDL is low</td>
    </tr>
    <tr>
      <td style="padding:10px; border:1px solid #2a2a3a;">Triglycerides</td>
      <td style="padding:10px; border:1px solid #2a2a3a;">Often reduced in metabolic dysfunction</td>
      <td style="padding:10px; border:1px solid #2a2a3a;">Modestly reduced</td>
      <td style="padding:10px; border:1px solid #2a2a3a;">Net reduction — favorable in men with high TG</td>
    </tr>
    <tr>
      <td style="padding:10px; border:1px solid #2a2a3a;">ApoB</td>
      <td style="padding:10px; border:1px solid #2a2a3a;">Data sparse; likely neutral</td>
      <td style="padding:10px; border:1px solid #2a2a3a;">Reduces ApoB 30–50%</td>
      <td style="padding:10px; border:1px solid #2a2a3a;">Net reduction — favorable</td>
    </tr>
  </tbody>
</table>

<p>The main concern is HDL. Both TRT (via hepatic lipase upregulation) and statins (modestly) can reduce HDL. For men with already-low HDL (&lt;40 mg/dL), the combination warrants more frequent monitoring and delivery method consideration — transdermal gel or daily SubQ produces less HDL impact than once-weekly IM.</p>

<h2>Liver Enzymes: What to Monitor</h2>
<p>Both statins and testosterone are processed by the liver. Elevated liver enzymes (AST, ALT) are a side effect risk for both independently:</p>
<ul>
  <li><strong>Statins:</strong> AST/ALT elevation in ~1–3% of users at high doses; severe hepatotoxicity is rare but documented</li>
  <li><strong>Oral testosterone (Jatenzo/Kyzatrex):</strong> First-pass hepatic metabolism; liver monitoring recommended</li>
  <li><strong>Injectable/transdermal TRT:</strong> Minimal direct liver impact at standard doses</li>
</ul>
<p>If you're on a statin and injectable TRT, your liver enzyme risk is low. If you're on a statin and <em>oral</em> TRT, check AST/ALT at baseline and at 3–6 month intervals. If you drink regularly, that adds a third liver stressor and all three should be disclosed to your prescriber simultaneously.</p>

<h2>Who Should Be Most Careful: 5-Scenario Decision Table</h2>
<table style="width:100%; border-collapse:collapse; margin: 16px 0;">
  <thead>
    <tr style="background:#1e1e2e;">
      <th style="padding:10px; text-align:left; border:1px solid #2a2a3a;">Scenario</th>
      <th style="padding:10px; text-align:left; border:1px solid #2a2a3a;">Risk Level</th>
      <th style="padding:10px; text-align:left; border:1px solid #2a2a3a;">Recommendation</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td style="padding:10px; border:1px solid #2a2a3a;">Injectable TRT + rosuvastatin or pravastatin</td>
      <td style="padding:10px; border:1px solid #2a2a3a;">🟢 Low</td>
      <td style="padding:10px; border:1px solid #2a2a3a;">Minimal interaction; standard monitoring is sufficient</td>
    </tr>
    <tr>
      <td style="padding:10px; border:1px solid #2a2a3a;">Injectable TRT + atorvastatin or simvastatin</td>
      <td style="padding:10px; border:1px solid #2a2a3a;">🟡 Low-moderate</td>
      <td style="padding:10px; border:1px solid #2a2a3a;">Watch for myopathy symptoms; check CK at baseline; generally well-tolerated</td>
    </tr>
    <tr>
      <td style="padding:10px; border:1px solid #2a2a3a;">Oral TRT (Jatenzo/Kyzatrex) + atorvastatin or simvastatin</td>
      <td style="padding:10px; border:1px solid #2a2a3a;">🟡 Moderate</td>
      <td style="padding:10px; border:1px solid #2a2a3a;">Discuss with prescriber; consider switching to rosuvastatin; monitor AST/ALT + lipids at 8–12 weeks</td>
    </tr>
    <tr>
      <td style="padding:10px; border:1px solid #2a2a3a;">Any TRT + statin + heavy training volume</td>
      <td style="padding:10px; border:1px solid #2a2a3a;">🟡 Moderate</td>
      <td style="padding:10px; border:1px solid #2a2a3a;">Highest myopathy risk scenario; watch CK; consider CoQ10; report muscle symptoms early</td>
    </tr>
    <tr>
      <td style="padding:10px; border:1px solid #2a2a3a;">Any TRT + statin + baseline HDL &lt;40 mg/dL</td>
      <td style="padding:10px; border:1px solid #2a2a3a;">🟠 Moderate-high</td>
      <td style="padding:10px; border:1px solid #2a2a3a;">Favor transdermal gel or daily SubQ TRT; monitor lipids every 3–6 months; cardiovascular risk context is critical</td>
    </tr>
  </tbody>
</table>

<h2>Monitoring Protocol: What Labs to Check and When</h2>
<table style="width:100%; border-collapse:collapse; margin: 16px 0;">
  <thead>
    <tr style="background:#1e1e2e;">
      <th style="padding:10px; text-align:left; border:1px solid #2a2a3a;">Lab</th>
      <th style="padding:10px; text-align:left; border:1px solid #2a2a3a;">Timing</th>
      <th style="padding:10px; text-align:left; border:1px solid #2a2a3a;">Why It Matters</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td style="padding:10px; border:1px solid #2a2a3a;">Full lipid panel (total cholesterol, HDL, LDL, TG, non-HDL)</td>
      <td style="padding:10px; border:1px solid #2a2a3a;">Baseline, 8–12 weeks, 6 months, annually</td>
      <td style="padding:10px; border:1px solid #2a2a3a;">Track HDL trend; confirm statin efficacy is maintained</td>
    </tr>
    <tr>
      <td style="padding:10px; border:1px solid #2a2a3a;">AST / ALT</td>
      <td style="padding:10px; border:1px solid #2a2a3a;">Baseline, 3–6 months (especially oral TRT)</td>
      <td style="padding:10px; border:1px solid #2a2a3a;">Liver enzyme monitoring for the statin + oral TRT combination</td>
    </tr>
    <tr>
      <td style="padding:10px; border:1px solid #2a2a3a;">Creatine Kinase (CK)</td>
      <td style="padding:10px; border:1px solid #2a2a3a;">Baseline; on-demand if muscle symptoms develop</td>
      <td style="padding:10px; border:1px solid #2a2a3a;">Myopathy detection; &gt;10× ULN warrants statin discontinuation</td>
    </tr>
    <tr>
      <td style="padding:10px; border:1px solid #2a2a3a;">Hematocrit / RBC</td>
      <td style="padding:10px; border:1px solid #2a2a3a;">8–12 weeks, 6 months, annually</td>
      <td style="padding:10px; border:1px solid #2a2a3a;">Standard TRT monitoring; hematocrit elevation adds cardiovascular context to the statin risk picture</td>
    </tr>
    <tr>
      <td style="padding:10px; border:1px solid #2a2a3a;">ApoB (optional but useful)</td>
      <td style="padding:10px; border:1px solid #2a2a3a;">Baseline and annually</td>
      <td style="padding:10px; border:1px solid #2a2a3a;">Better atherogenic particle assessment than LDL-C when HDL is fluctuating due to TRT</td>
    </tr>
    <tr>
      <td style="padding:10px; border:1px solid #2a2a3a;">Total testosterone (trough)</td>
      <td style="padding:10px; border:1px solid #2a2a3a;">8–12 weeks, 6 months, annually</td>
      <td style="padding:10px; border:1px solid #2a2a3a;">Confirm TRT target levels maintained; statin is not affecting exogenous T levels meaningfully</td>
    </tr>
  </tbody>
</table>

<h2>Does TRT Reduce the Need for Statins?</h2>
<p>This is a real clinical question that doesn't get asked often enough. In men with metabolic syndrome, low testosterone contributes directly to:</p>
<ul>
  <li>Elevated triglycerides</li>
  <li>Reduced insulin sensitivity</li>
  <li>Visceral fat accumulation</li>
  <li>Higher LDL particle number</li>
</ul>
<p>In some men, successful TRT — when combined with exercise and dietary improvement — improves the metabolic profile enough that the prescribing physician reassesses the statin indication. This happens more frequently than the clinical literature acknowledges. It is not a reason to avoid a statin if your cardiovascular risk warrants one. But it's worth flagging as a possibility to discuss after 12–18 months of optimized TRT.</p>

<h2>CoQ10: Should You Take It?</h2>
<p>Statins reduce coenzyme Q10 (CoQ10) levels by approximately 30–50%, via the same HMG-CoA pathway suppression. CoQ10 is critical for mitochondrial ATP production — the same energy system that muscles depend on.</p>
<p>CoQ10 supplementation (100–200mg ubiquinol form) is one of the most commonly cited myopathy management strategies. The clinical trial evidence is mixed — some trials show symptom improvement, others do not. But the risk is extremely low and cost is minimal. Men on statins + TRT who are training intensively have the most logical reason to try it.</p>

<h2>Summary: Key Points for Men on Both</h2>
<ul>
  <li>✅ TRT and statins are not contraindicated — they are routinely co-prescribed</li>
  <li>🔍 The main risk to monitor is <strong>statin myopathy</strong>, especially if you're training hard on TRT</li>
  <li>🔍 <strong>HDL</strong> deserves close monitoring — both agents can reduce it; track trend, not single value</li>
  <li>⚠️ <strong>Oral TRT + atorvastatin/simvastatin</strong> is the combination most worth discussing with your prescriber due to shared CYP3A4 metabolism</li>
  <li>✅ Injectable or transdermal TRT with rosuvastatin or pravastatin has the lowest interaction profile</li>
  <li>📋 Get CK at baseline; monitor AST/ALT if on oral TRT; recheck lipids at 8–12 weeks post-TRT start</li>
</ul>

<div style="border: 1px solid #2a2a3a; border-radius: 8px; padding: 16px; margin: 24px 0; background: #12121a;">
  <p style="font-weight: 600; margin-bottom: 8px;">On statins and evaluating TRT?</p>
  <p style="margin-bottom: 12px;">Our quiz maps your cardiovascular risk factors, metabolic health, and goals to the right TRT starting path — including how to frame the conversation with your prescriber.</p>
  <a href="/quiz" style="display: inline-block; background: #6366f1; color: white; padding: 10px 20px; border-radius: 6px; text-decoration: none; font-weight: 600;">Take the Free TRT Decision Quiz →</a>
</div>

<h2>Frequently Asked Questions</h2>
<p><strong>Can you take testosterone replacement therapy while on a statin?</strong><br/>Yes. TRT and statins are not contraindicated. They are commonly co-prescribed, particularly in men with cardiovascular risk factors who are also hypogonadal. The key considerations are monitoring for myopathy, tracking HDL, and being more careful with oral TRT + CYP3A4-dependent statins (atorvastatin, simvastatin).</p>
<p><strong>Do statins lower testosterone levels?</strong><br/>The evidence is mixed. Some studies show modest reductions (~19 ng/dL) with lipophilic statins like atorvastatin and simvastatin. Hydrophilic statins (rosuvastatin, pravastatin) show minimal effect. However, if you're on exogenous TRT, the statin effect on endogenous production is irrelevant — your levels are set by dose, not Leydig cell function.</p>
<p><strong>What is the best statin to take with TRT?</strong><br/>Rosuvastatin (Crestor) and pravastatin (Pravachol) have the least pharmacokinetic interaction with testosterone. They do not depend on CYP3A4 for metabolism. If you're on oral TRT specifically, these are preferable over atorvastatin or simvastatin. That said, any statin can be used with injectable TRT without significant concern.</p>
<p><strong>Can TRT cause statin myopathy?</strong><br/>TRT does not directly cause statin myopathy. But TRT increases training intensity and muscle protein synthesis — which puts more mechanical stress on the same muscle tissue that statins compromise via CoQ10 depletion. The result is that men who tolerated a statin fine before TRT may experience muscle symptoms after starting TRT. This is an indirect effect via exercise intensity, not a direct pharmacological interaction.</p>
<p><strong>Should I tell my prescriber I'm on TRT before starting a statin?</strong><br/>Yes — always disclose TRT to any prescriber managing your cardiovascular health. It affects lipid interpretation (especially HDL), cardiovascular risk framing, and helps your doctor choose the appropriate statin and monitoring schedule.</p>
<p><strong>Does TRT affect how well statins work?</strong><br/>There is no evidence that TRT reduces statin efficacy. The LDL-lowering effect of statins is primarily hepatic and is not blunted by testosterone. In some men with metabolic syndrome, TRT improves insulin sensitivity and reduces triglycerides in ways that complement statin therapy.</p>
<p><strong>Can TRT replace the need for a statin?</strong><br/>Not directly. Statins have robust RCT evidence for reducing cardiovascular events in high-risk populations — that evidence is for the statin itself, not for testosterone. However, men on optimized TRT who significantly improve their metabolic profile (body composition, TG, insulin sensitivity) may find their prescriber reassesses statin necessity after 12–18 months. This is a clinical conversation, not a DIY decision.</p>
<p><strong>Should I take CoQ10 if I'm on statins and TRT?</strong><br/>It's a reasonable option, especially if you're training intensively. Statins reduce CoQ10 by 30–50%. The clinical trial evidence for myopathy prevention is mixed, but CoQ10 (100–200mg ubiquinol form) is low-risk and widely used. It's not essential but makes sense if you're experiencing fatigue or muscle symptoms.</p>

<p>Related: <a href="/blog/testosterone-and-cholesterol">Testosterone and Cholesterol →</a> | <a href="/blog/trt-and-cardiovascular-health">TRT and Heart Health →</a> | <a href="/blog/testosterone-and-diabetes">Testosterone and Insulin Resistance →</a> | <a href="/blog/oral-testosterone">Oral Testosterone (Jatenzo, Kyzatrex) →</a> | <a href="/blog/trt-bloodwork-panel">TRT Bloodwork Panel →</a> | <a href="/blog/trt-protocol-optimization">TRT Protocol Optimization →</a>`
};
